- Home
- LNKB vs NPCE Comparison
LNKB vs NPCE Comparison
Compare LNKB & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- NPCE
- Stock Information
- Founded
- LNKB 2018
- NPCE 1997
- Country
- LNKB United States
- NPCE United States
- Employees
- LNKB N/A
- NPCE N/A
- Industry
- LNKB
- NPCE Medical Specialities
- Sector
- LNKB
- NPCE Health Care
- Exchange
- LNKB Nasdaq
- NPCE Nasdaq
- Market Cap
- LNKB 256.4M
- NPCE 292.9M
- IPO Year
- LNKB N/A
- NPCE 2021
- Fundamental
- Price
- LNKB $7.23
- NPCE $9.03
- Analyst Decision
- LNKB Strong Buy
- NPCE Strong Buy
- Analyst Count
- LNKB 1
- NPCE 6
- Target Price
- LNKB $9.00
- NPCE $16.67
- AVG Volume (30 Days)
- LNKB 37.5K
- NPCE 195.6K
- Earning Date
- LNKB 07-28-2025
- NPCE 08-12-2025
- Dividend Yield
- LNKB 4.17%
- NPCE N/A
- EPS Growth
- LNKB N/A
- NPCE N/A
- EPS
- LNKB 1.01
- NPCE N/A
- Revenue
- LNKB $121,982,000.00
- NPCE $88,570,000.00
- Revenue This Year
- LNKB $21.03
- NPCE $21.04
- Revenue Next Year
- LNKB N/A
- NPCE $10.73
- P/E Ratio
- LNKB $7.13
- NPCE N/A
- Revenue Growth
- LNKB 79.01
- NPCE 23.32
- 52 Week Low
- LNKB $6.00
- NPCE $5.45
- 52 Week High
- LNKB $7.98
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- LNKB 57.94
- NPCE 41.86
- Support Level
- LNKB $6.57
- NPCE $7.56
- Resistance Level
- LNKB $7.53
- NPCE $9.68
- Average True Range (ATR)
- LNKB 0.24
- NPCE 0.52
- MACD
- LNKB 0.04
- NPCE 0.13
- Stochastic Oscillator
- LNKB 83.85
- NPCE 64.13
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.